In experiments in rats and mice, two Johns Hopkins scientists report the successful use of nanoparticles to deliver gene therapy for blinding eye disease.

New NEI-supported research provides insight into the eye conditions associated with Marfan syndrome, where weakened zonule fibers cause vision problems.

University of Maryland-led study identified the first gene responsible for eye loss in cavefish, revealing connection to a human vascular disease.

The Knights Templar Eye Foundation has awarded two NEI scientists grants to research inherited retinal degenerations, diseases that can cause blindness in early childhood.

A small pilot clinical study at the National Eye Institute (NEI) suggests that the drug nitisinone increases melanin production in some people with oculocutaneous albinism type 1B (OCA-1B), a rare genetic disease that causes pale skin and hair and poor vi

A new form of therapy may halt or even reverse a form of progressive vision loss, spinocerebellar ataxia type 7 (SCA7). This new therapy has the potential to treat neurogenetic diseases effectively and with far fewer side effects than other medications.

Scientists funded by the National Eye Institute (NEI) report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP).

National Eye Institute (NEI) Postdoctoral Fellow Aman George, Ph.D., has received a $65,000 grant from the Knights Templar Eye Foundation to identify new drug treatments for vision impairment in children with a type of albinism.

Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI).

The breast cancer drug tamoxifen appears to protect light-sensitive cells in the eye from degeneration, according to a new study in mice.